Differential Immune Effects of Natalizumab

A Phase IV Study to Investigate Differential Immune Effects of Natalizumab

Natalizumab is a humanized monoclonal antibody directed against Very Late Activation Antigene 4 (VLA-4) and has a potent effect on disease activity in multiple sclerosis (MS). A blockade of VLA-4 with natalizumab may not only interfere with autoimmunological processes but also with central nervous system (CNS) immune surveillance.

Longitudinal ex vivo and in vitro study to determine the effect of natalizumab on frequency of distinct immune cells and on the frequency and suppressive function of natural CD4+CD25+ regulatory T cells (Tregs).

Inclusion Criteria:

• relapsing remitting MS
• indication for natalizumab treatment

Exclusion Criteria:

• other disease modifying agents within 2 weeks